ADVICENNE Aktie

 

Sibnayal® end-market sales (Europe and Middle East) up 103% to €5.5 million H1 products sales and royalties totaled €3.1 million, up 20% Financial visibility extended to the fourth quarter of 2026 thanks to debt restructuring and a €2.6 million capital increase last July Favorable outlook with the continued commercial momentum of Sibnayal® in its main markets and the filing of the marketing authorization application for ATRd in the United States anticipated in the fourth quarter of 2025 PARIS--(BUSINESS WIRE)--Regulatory News: Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, today reports its 2025 first half financial results, as approved on September 19, 2025 by the Board of Directors. The first half financial report is available on the Company's website: www.advicenne.com. Didier Laurens, Chief Executive Officer of Advicenne, commented: "The...

PARIS--(BUSINESS WIRE)--Regulatory News: Advicenne (Euronext Growth® - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, reports first half of 2025 sales of €2.6 million, up 9% compared to the first half of 2024. The reported turnover does not include royalties to be received from partners during this period. Direct sales, booked by Advicenne, rose 17% to €1.27 million. Performance in France was particularly strong with a growth of 48% during the reported period. Overall, sales of Sibnayal® in its European end markets represent €5.18 million, up 90% versus H1 2024. Turnover (m€) H1 2025 H1 2024 Growth Sibnayal® 1,27 1,08 +17% Neurology 1,36 1,33 +2% Of which Likozam® 1,02 0,99 +3% Of which Levidcen® 0,33 0,34 -3% Total 2,63 2,42 +9% At the date of this press release, the Company's cash flow horizon is Q3 2026, thanks to the recent capital increase and the completion of its deb...

Das Instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY wird ex Kapitalmassnahme gehandelt am 02.07.2025 The instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY is traded ex capital adjustment on 02.07.2025...

PARIS--(BUSINESS WIRE)--Regulatory News: Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare renal diseases, announces today that its 2024 Universal Registration Document has been filed with the French Autorité des Marchés Financiers (AMF). The Universal Registration Document includes the annual report, the management report, the Board of Directors' report on corporate governance and the Statutory Auditors' reports. It also contains a description of the share buyback program. The Universal Registration Document is available on Advicenne's website (www.advicenne.com) in the Investors/Financial Information section and on the AMF website (www.amf-france.org). About Advicenne Advicenne (Euronext: ALDVI) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal® (ADV71...

Total product sales of Advicenne up 9.4% to €4.9m Operating cash consumption below €1M by 2025 and significant improvement in cash flow Cash position of €3.2 million on December 31, 2024, with a financing horizon of end-June 2025 European in-market sales of Sibnayal® up over 130% to €6.0M and royalties received in excess of €0.5M Major regulatory advances for ADV7103 / Sibnayal® in the United States in its two indications (dRTA and cystinuria) Favorable outlook with the filing of ADV7103 in dRTA in the United States, expected in Q3 2025 PARIS--(BUSINESS WIRE)--Regulatory News: Advicenne (Euronext Growth Paris ALDVI – FR0013296746) a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare renal diseases, announces today its 2024 financial results, and provides an update on its activities. The financial statements for the year 2024 were approved by the Board of Directors at its meeting on March 27, 2025. The aud...

2024 Gross sales reported at €4.8 million, up 9.2%. Gross sales of Sibnayal® (potassium citrate / potassium bicarbonate) in France recorded an impressive 40% growth. Royalties for 2024 are estimated at €0.5 million in addition to reported gross sales. End-market estimated global sales of Sibnayal® in Europe and Middle East, reaching €6.0 million, up 135% compared to 2023. PARIS--(BUSINESS WIRE)--Regulatory News: Advicenne (Euronext Growth Paris ALDVI – FR0013296746) a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare renal diseases, today announces that gross sales reached €4.8 million for the 2024 financial year, up 9.2% on the previous year. Gross sales do not include royalties from partners on sales in their respective territories, estimated at €0.5 million for 2024. Sibnayal® mostly drove the growth with reported gross sales of €2.2 million, up by almost 14%. In France, the performance was solid, ...